Page 1 of 44

Use of digital technology tools to characterize patient adherence to prescription-grade omega-3 polyunsaturated fatty acid therapy: Primary results of

4 the DIAPAsOn prospective observational study

- 5
- 6 Gregory P. Arutyunov MD, PhD,^{1*} Alexander G. Arutyunov MD, PhD,² Fail
- 7 T. Ageev MD PhD,³ Tatiana V. Fofanova MD, PhD⁴
- 8
- 9 ¹Department of Internal Medicine, Pirogov Russian National Research Medical University, 10 Moscow. e-mail: arut@ossn.ru 11 12 ORCID: 0000-0002-6645-2515 13 14 15 ²Department of Internal Medicine, Pirogov Russian National Research Medical University, 16 Moscow. email: agarutyunov@mail.ru 17 18 ORCID: 0000-0003-1180-3549 19 20 ³Department of Outpatient Medical and Diagnostic Technologies, Myasnikov Institute of 21 22 Clinical Cardiology, National Medical Research Center for Cardiology, Moscow. email: 23 ftageev@gmail.com 24 25 ORCID: 0000-0003-4369-1393 26 27 ⁴Department of Outpatient Medical and Diagnostic Technologies, Myasnikov Institute of 28 Clinical Cardiology, National Medical Research Center for Cardiology, Moscow. email: t.fofanova@vandex.ru 29 30 31 ORCID: 0000-0002-3321-2902 32 *Author for correspondence 33 Keywords: Omega-3-acid ethyl esters; myocardial infarction; hypertriglyceridemia, 34 35 adherence; compliance; persistence; mhealth; ehealth; patient-reported outcomes

Page 2 of 44

37 Abstract

- 38 **Background, objectives and methods:** DIAPAsOn was a 6-month prospective
- 39 observational multicenter study in the Russian Federation that examined adherence to
- 40 a preparation of highly purified omega-3 polyunsaturated fatty acids (OMACOR) in
- 41 adult patients with a history of recent myocardial infarction or endogenous
- 42 hypertriglyceridemia. A full description of the study's aims and methods has appeared
- 43 in *JMIR Res Protoc.* A feature of DIAPAsOn was the use of a bespoke electronic
- 44 patient engagement and data collection system.
- 45 **Results:** The net average reduction from baseline in both total and low-density
- 46 lipoprotein cholesterol was approximately 1 mmol/L and the net average increment in
- 47 high-density lipoprotein cholesterol was 0.2±0.53 mmol/L. Mean triglyceride levels
- 48 declined by ~1.3 mmol/, from an initial level of 2.99±1.29 mmol/L to 1.67± 0.67
- 49 mmol/L. The percentage of patients with triglyceride <1.7 mmol/L rose from 13.1% at
- 50 baseline to 54% at study-end.
- 51

52 Digital reporting of adherence was registered by 8.3% of patients (n=180) and average

- 53 scores indicted poor adherence. However, clinic-based enquiry suggested high levels
- 54 of adherence.
- 55

56 Data on health-related quality of life accrued from digitally-engaged patients identified 57 improvements among patients reporting high adherence to study treatment, but

- 58 patient numbers were small.
- 59
- 60 Conclusions: The lipid and lipoprotein findings indicate that OMACOR had nominally
- 61 favorable effects on the blood lipid profile. Less than 10% of patients enrolled in
- 62 DIAPAsOn used the bespoke digital platform piloted in the study and the level of self-
- ⁶³ reported adherence to medication by those patients was also low. Reasons for this low
- 64 uptake and adherence are unclear. Better adherence was recorded by clinical report.

Page 3 of 44

66 Introduction

- Non-high-density lipoprotein cholesterol blood lipids are a source of residual
- 68 cardiovascular risk in patients whose low-density lipoprotein cholesterol (LDL-C) levels
- are well controlled by medication, primarily statins [1-9].
- 70

71 Optimal risk reduction in cardiovascular disease, as in other forms of major non-

communicable diseases, depends substantially on patients continuing to take their

73 medications for extended periods of time. This can be a particular challenge in

74 conditions such as hyperlipidemia, where the connection between symptomless

elevations of blood lipid levels and major cardiovascular events can seem abstract orremote [10,11].

Recent comparative research in Russia and Norway has disclosed poor attainment of 77 78 cholesterol targets in both countries, despite a notably higher prescription rate of these 79 drugs in Norway [12]. Suboptimal patient adherence to prescribed treatments is likely 80 to be a contributor to such findings, which illustrates that the challenges of promoting 81 and sustaining adherence to therapy are not confined to any one country. It is nevertheless clear from the results of the CEPHEUS II study that failure to reach 82 83 targets for lipid-based risk reduction is widespread in Russia [13]. Patient-related factors associated with non-attainment of targets identified in that study included 84 85 considering it acceptable to miss prescribed doses more than once per week. Poor 86 adherence to medication for hypertension has likewise been documented in the 87 Izhevsk Family Study II [14].

Those findings exemplify observations that the rates of both discontinuation and nonadherence to therapy are uniformly high in clinical trials of lipid-lowering drugs and even higher in unselected populations, with adherence deteriorating in proportion to the duration of follow-up [15]. Analysis of a large Swiss healthcare claims database (N=4349) revealed that overall adherence to drug therapy for secondary

93 cardiovascular prevention after myocardial infarction (MI) was only moderate, but that

94 patients with high adherence to lipid-lowering therapy had a significantly reduced risk

95 for all-cause mortality and major cardiovascular events, illustrating the potential for

96 improvement of longer-term outcomes [16].

Page 4 of 44

98 OMACOR (hereafter OM3EE; license holder Abbott Laboratories GmbH) is a 99 preparation of highly purified long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (eicosapentanoic acid/docosohexanoic acid in a 1.2:1 ratio and 90% purity) 100 available as a prescription-only medication and widely approved for use, at a daily 101 102 dose of 1 g, for the secondary prevention of major cardiovascular events in patients 103 who have survived an MI, or at doses of 2-4 g/day for the regulation of triglycerides 104 (TG). Prescription-only n-3 PUFAs (PnP) such as OM3EE are gualitatively distinct 105 from dietary n-3 PUFA supplements and have been evaluated in a range of clinical

- 106 trials [17,18].
- 107 The emergence of widely available digital and internet technologies with the potential
- 108 to provide immediate bidirectional communication between healthcare professionals
- 109 (doctors, nurses and pharmacists) and patients may be an important new resource for
- 110 promoting long-term adherence to therapies [19]. The DIAPAsOn study was devised
- 111 to explore patient adherence to OM3EE therapy through the medium of digital
- 112 technology tools.
- 113

115

117

114 Methods

116 <u>Overview</u>

- 118 A comprehensive description of the methodology of the DIAPAsOn study has been
- 119 published, including baseline demographic data [20].
- 120
- 121 Briefly, DIAPAsOn was a prospective observational study conducted at >100 centers
- 122 in the Russian Federation and devised to examine adherence to a prescription of
- 123 OM3EE as either a secondary preventive medical therapy (at a dose of 1 g/day) for
- 124 patients with a history of recent MI or for blood lipid regulation (at doses of 2–4 g/day)
- 125 in patients with endogenous hypertriglyceridemia insufficiently responsive to dietary
- 126 modification or drug therapy.
- 127
- 128 Participants were required to be adults (≥18 years) with a history of MI for whom
- 129 OM3EE was prescribed as part of a secondary prevention strategy or to have
- 130 Fredrickson endogenous type IIb or III hypertriglyceridemia not satisfactorily controlled
- 131 by statin therapy or Fredrickson endogenous type IV hypertriglyceridemia not

Page 5 of 44

- sufficiently controlled by a lipid-moderating diet. In addition, patients should have been
 taking OM3EE for not >2 weeks prior to enrolment.
- 134

135 DIAPAsOn is registered at www.ClinicalTrials.gov (NCT03415152).

136

137 Schedule of visits and data collection

- 138 The DIAPAsOn study had a scheduled duration of 6 months. Clinic visits were
- 139 scheduled at the start of the study (Visit 1) and then at approximately 3 months (Visit
- 140 2) and at the end of the study (Visit 3). At each of the three scheduled clinic visits,
- 141 patients were questioned about compliance with OM3EE therapy using the
- 142 Questionnaire of Treatment Compliance [21]. This instrument, which has been used in
- 143 Russia to investigate compliance with other cardiovascular medications, produces a
- numerical indication of compliance, as follows: 12–15 points, very high; 8–11 points,
- 145 high; 4–7, moderate; and 0–3, low.
- 146
- Blood lipid profile was determined at each visit, along with blood pressure and heart
 rate data, adverse events and hospitalization were recorded. Patients also received
- 149 inter-visit phone calls focused on adherence to therapy and safety.
- 150
- 151 A central aspect of DIAPAsOn was the use of remote digital technology that allowed
- 152 patients to submit data and report on matters such as health-related quality of life
- 153 (HRQoL) and product usability (very good, good, moderate, poor).
- 154
- 155 The electronic patient engagement and data collection system used in DIAPAsOn was 156 developed in collaboration with the medical online platform ROSMED.INFO (Moscow,
- 157 Russian Federation; <u>www.rosmed.info</u>), which has wide-ranging experience in the
- 158 development and operation of mobile health applications in the Russian Federation. A
- 159 fuller description of the system used in DIAPAsOn featured in the separate publication
- 161

160

of methodology [20].

- 162 All aspects of the DIAPAsOn study, including the associated mobile health app,
- 163 conformed to relevant extant national and international legal and ethical regulations
- and requirements for the conduct of clinical research in human subjects, including the

Page 6 of 44

165 provisions of the Declaration of Helsinki, including patients' right to decline further participation in DIAPAsOn at any time and for any reason, whether stated or not, 166 without prejudice to their subsequent treatment. Ethical oversight of the DIAPAsOn 167 study was exercised by the independent Interuniversity Ethics Committee (Moscow, 168 169 Russian Federation). A list of center investigators appears in Appendix 1. 170 171 Statistical methods 172 Methods were predominantly descriptive, conducted in accordance with the pre-173 approved statistical analysis plan, and used the statistical programming language R 174 (version 3.4.3; https://mran.microsoft.com/releases/3.4.3). 175 The primary endpoint—adherence to therapy with OM3EE in post-MI patients or 176 177 patients with hypertriglyceridemia—was assessed in an analysis population, defined 178 as those patients for whom data were obtained at least at Visits 1 and 2. 179 180 Analysis of the primary endpoint included determination at the end of the study (Visit 181 3) of the mean adherence rate, which was defined as the number of days for which the patient took the full prescribed dose of OM3EE during the specified period divided by 182 183 the total number of days in that period. The mean score on the National Questionnaire 184 of Treatment Compliance was calculated at the same time. 185 Comparison of individual patient data between visits was based on either Student's t-186 187 test (for dependent variables) or McNemar's test (for qualitative data). 188 189

Page 7 of 44

190 **Results**

191

A total of 3000 patients were initially included in the program but 428 (14.3%) were excluded because Visit 1 data were incomplete. Valid and complete data from Visit 1 were available for 2572 patients (85.7%), who constituted the safety population. After exclusion of 405 patients lost before Visit 3, an analysis population of 2167 patients was derived, representing 72.2% of total enrolled patients (Figure 1), of whom 898 (41.4%) were taking OM3EE for secondary prevention after MI and 1269 (58.6%)

- 198 were taking OM3EE for hypertriglyceridemia.
- 199 DIAPAsOn was completed per protocol by 1975 patients (secondary prevention,
- 200 n=780; hypertriglyceridemia, n=1195). This was an almost wholly Caucasian
- 201 population (97.74%) with a near-equal sex distribution (men, 52.8%; women, 47.2%),
- an average age of \approx 60 years and an average body mass index (BMI) of 30 kg/m².
- 203 There were more men than women in the secondary prevention subgroup (n=608;
- 204 67.7%), whereas women outnumbered men in the hypertriglyceridemia subgroup
- 205 (n=732; 57.68%). Investigator-assessed 'clinically significant' abnormalities of systolic
- and diastolic blood pressure (BP) were recorded in 21.4% and 12.8% of patients,
- 207 respectively.

As illustrated in Figure 1, 180 of the 2167 patients who comprised the analysis

209 population (8.3%) submitted data via the mobile health platform, of whom 93 were

210 enrolled in DIAPAsOn on the basis of previous MI and 87 on a diagnosis of qualifying

211 hyperlipidemia. From start to finish, three of the initial grouping of 183 patients who

used the mobile health platform (1.6%) were withdrawn from the study or discontinued

it, compared with 1025 of 2817 (36.4%) of those who did not submit data via the

214 mobile platform. After establishment of the analysis population, early termination rates

- were 0% and 9.7%, respectively (Figure 1).
- 216

217 Compliance with OM3EE

The mean duration of OM3EE administration was 166.5±70.6 days (median, 199

219 days; range, 14–268 days).

220

Among the 2167 patients whose compliance was monitored at clinical visits but not self-reported via the mobile app, the mean score on the National Questionnaire of

Page 8 of 44

Treatment Compliance at Visit 3 was 13 ± 3 points, signifying high overall compliance with therapy. Mean scores >12 were also recorded at Visit 1 (12.5 ±3.1) and Visit 2 (13 ±2.9). Relative to the mean score at Visit 1, the mean scores at both Visits 2 and 3 were statistically significantly larger (p<0.001) (Table 1). The distribution of adherence categories for the total study population and for the two subpopulations of DIAPAsOn is shown in Figure 2. Overall, high or very high compliance was recorded for >90% of respondents in both subseries.

230

A total of 69 patients (2.68%) discontinued OM3EE during the study. Numerically, the

largest groups to do so were patients who cited inconvenience of use (n=11) and

those who reported absence of stock at pharmacies (n=6). A total of 50 patients

discontinued for a plurality of reasons, including cost of medication, reluctance to

commit to long-term medication discontinued by another physician, normalization of

blood lipid values and change of residence.

237

Inconvenience of use was more often recorded in patients enrolled in DIAPAsOn for
hypertriglyceridemia than for secondary prevention (19% vs 5.9% of total cases).

Among the 180 patients who registered data via the DIAPAsOn mobile platform, 241 242 adherence to therapy, expressed as the ratio of days when the full prescribed dose of OM3EE was taken to the total number of days in the treatment period, averaged 243 244 0.37±0.38 over the entire program, corresponding to a low level of adherence. Mean 245 adherence between Visits 1 and 2 was 0.48±0.4, while that between Visits 2 and 3 246 was 0.24±0.4 (p<0.001). Between Visits 1 and 2, 50.0% of patients had low adherence 247 (<0.5), 15.56% had moderate adherence (0.5–0.7) and 34.44% had high adherence (≥0.8). Between Visits 2 and 3, the proportion of patients with low adherence 248 increased to 75.0%, while the proportion with high adherence decreased to 20.56%. 249 250 When the data were stratified by adherence level there was an essentially binary split, with most patients reporting either low adherence (74.44%) or high adherence (25%). 251

252

In the subgroup of 93 patients taking OM3EE for secondary prevention after MI and
 self-reporting adherence via the study app, mean adherence between Visits 1 and 3

was 0.47±0.39, with 66.67% of patients recording low adherence and 32.26% high

Page 9 of 44

256	adherence. Mean adherence in that subgroup at Visit 2 reached 0.6±0.38; at Visit 3 it
257	had decreased to 0.33±0.45 (p<0.001 for trend). At Visit 2, 32.26% of patients had low
258	adherence (<0.5) and 45.16% had high adherence (≥0.8). By Visit 3, the proportion of

- 259 patients with low adherence had increased to 67.74%, while the proportion with high
- adherence had declined to 30.11%.
- 261

Among the 87 app-using patients taking OM3EE for hypertriglyceridemia, mean

- adherence between Visits 1 and 3 was 0.25±0.33, with most patients (82.76%) self-
- reporting low adherence, and 17.24% recording high adherence. In this subgroup,
- 265 68.97% of patients had low adherence (<0.5) at Visit 2 and 22.99% had high
- adherence (≥ 0.8). By Visit 3, those percentages had changed to 82.76% and 10.34%,
- respectively.
- 268

269 Cross-referencing of the results on the National Questionnaire of Treatment

- 270 Compliance administered at clinic visits with self-reported adherence based on the
- 271 ratio of administered and prescribed dose established that, among patients identified
- by their response to the National Questionnaire as having 'very high', 'high' or
- ²⁷³ 'moderate' adherence to therapy, app-reported mean adherences for the time period
- between Visits 1 and 2 were 50.04%, 52.85% and 24.58%, respectively, while
- between Visits 2 and 3 adherence was 28.67% for those assessed as having 'very
- high' adherence by questionnaire, 19.11% for those in the 'high' category and 5.57%
- for those in the 'moderate' category.

278

In the analysis population as a whole, 64.5% of patients rated the usability of OM3EE
after 1 month of treatment as 'very good'. A further 29.9% and 5.6%, respectively
rated usability as 'good' or 'moderate'. No patient rated usability as 'poor'. All the
patients prescribed OM3EE for secondary prevention post-MI rated the usability as
'very good' (70.7%) or 'good' (29.3%), while, among patients treated for
hypertriglyceridemia, the usability of OM3EE was rated as 'very good' by 57.1% of
patients, 'good' by 30.6% and 'moderate' by 12.2%.

- 287
- 288
- 289

Page 10 of 44

290 Lipid indices

- 291 At baseline, investigator-classified 'clinically significant' deviations from normal for total
- 292 cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C) and TG were
- recorded in 46.1%, 40.93%, 14.4% and 64.97% of patients, respectively. Mean values
- 294 of TC, TG, LDL-C, HDL-C and non-HDL-C (n-HDL-C) were 5.55±1.39, 2.99±1.29,
- 295 3.5±1.25, 1.27±0.46 and 4.29±1.47 mmol/L, respectively.
- 296
- 297 In-study trends in mean blood lipid levels are depicted in Figure 3 for the overall
- 298 DIAPAsOn cohort and for the two subpopulations differentiated by indication.
- 299
- 300 Analysis of lipid profile stratified by baseline TG status revealed that increasing TG
- 301 levels were associated with trends in TC that were potentially deleterious to
- 302 cardiovascular health (Table 2).

- Lipid profile parameters were recorded at baseline at Visit 1, as well as after 3 months
- 305 (Visit 2) and 6 months (Visit 3) of follow-up. Mean TC at Visit 1 was 5.55±1.39 mmol/L.
- 306 This had decreased to 4.54±1.04 mmol/L (p<0.001) by Visit 2, and at Visit 3 had been
- 307 further reduced, to 4.17±1.04 mmol/L (p<0.001). Across the period of observation, the
- 308 net average change in mean TC was thus –1.32±1.28 mmol/L.
- 309
- At Visit 2, mean LDL-C was 2.71±0.94 mmol/L, an average reduction from Visit 1 of
- 311 0.77±0.92 mmol/L (p<0.001). Further reduction was observed at Visit 3, when the
- mean LDL-C level was 2.46±0.76 mmol/L (p<0.001 vs Visit 1). The average net
- decrement in LDL-C was thus 1.02±1.02 mmol/L.
- 314
- Mean HDL-C levels at Visits 1, 2 and 3 were, respectively, 1.27±0.46, 1.41±0.42
- 316 (p<0.001 vs Visit 1) and 1.44±0.42 mmol/L (p<0.001 vs Visit 1), with an average
- increment of 0.2±0.53 mmol/L over the period of observation.
- 318
- n-HDL-C declined by an average of 1.6±1.54 mmol/L during the period of observation,
- 320 falling from 4.27±1.47 mmol/L at Visit 1 to 3.14±1.12 mmol/L at Visit 2 (p<0.001 vs
- 321 Visit 1) and to 2.71±1.0 mmol/L at Visit 3 (p<0.001 vs Visit 1).
- 322

Page 11 of 44

Mean TG was 3.0±1.3 mmol/L at Visit 1, 2.0±0.9 mmol/L at Visit 2 and 1.7±0.7 mmol/L at Visit 3 (p<0.001 for both vs Visit 1). The overall average reduction in mean TG was thus 1.32±1.15 mmol/L across the observation period.

326

Trends in overall TG levels during DIAPAsOn are displayed in more detail in Table 3, with patients assigned to one of three baseline distribution categories. Statistically significant changes in that distribution towards lower levels of TG were apparent at both Visits 2 and 3, with the percentage of patients recorded as having TG <1.7 mmol/L increasing from 13.1% at baseline to 54% at the conclusion of the study period, while the percentage recorded as having TG >2.3 mmol/L fell from 66.9% to 10.4%.

334

335 The average differences in TC, LDL and n-HDL-C between baseline and Visit 3 were a function of baseline TG. Thus, the reductions in patients with initial TG >2.3 mmol/L 336 were -1.47, -1.1 and -1.7 mmol/L, respectively, while in patients with initial TG 1.7-337 338 2.3 mmol/L, the average intra-study changes from baseline to Visit 3 were -1.16, -339 0.99 and -1.32 mmol/L. In patients with initial TG <1.7 mmol/L the average changes in 340 TC, LDL and n-HDL-C were -0.83, -0.63 and -0.94 mmol/L, respectively. Significance was nevertheless apparent (p<0.001) for each parameter in each of those subgroups. 341 342 The mean change in HDL during observation versus baseline was +0.24 mmol/L in patients with TG >2.3 mmol/L (p<0.001), +0.16 mmol/L in patients with TG 1.7-2.3 343 344 mmol/L (p<0.001) and +0.09 mmol/L in patients with TG <1.7 mmol/L (p=0.002). A 345 statistically significant decrease in TG at Visit 3 versus baseline was observed only in 346 subgroups of patients with baseline TG >2.3 or 1.7-2.3 mmol/L (-1.81 and -0.55 347 mmol/L, respectively; p<0.001 for both subgroups).

348

349 Sub-analysis of the patients being treated for hypertriglyceridemia stratified according 350 to the concomitant use/non-use of statins and/or fibrates identified no substantial or

351 significant inter-group differences in baseline levels of blood lipid components.

352 Subsequent in-study trends in blood lipid fractions in both these subgroups are

353 summarized in Table 4 and indicate significant longitudinal trends in both subgroups

354 (p<0.001 for all indices in both comparisons) and slightly more pronounced responses

in those who were taking additional lipid-regulating drugs in combination with OM3EE.

Page 12 of 44

Formal tests for inter-subgroup differences depending on the use/non-use of statins orfibrates were not conducted.

358

359 Changes between baseline and Visit 3 stratified by self-reported adherence registered

- 360 via the study mobile app (n=180) identified no correlations or associations between
- 361 the level of adherence and absolute changes in levels of lipids or lipoproteins.
- 362 The results of investigations into the relationship between rates of adherence and
- 363 patient demographic factors for the whole analysis population are summarized in the
- 364 Supplementary Tables.
- 365

366 <u>HRQoL outcomes</u>

367 HRQoL data accrued from patients who contributed to the digital data collection

368 element of DIAPAsOn are summarized in Table 5. Data for the 'General Health'

369 domain were excluded due to a technical error during data transfer. Statistically

370 significant increases in the scores for all domains except pain were recorded during

371 the observation period. Further analysis, stratified by self-reported adherence to

372 therapy (low, moderate or high), indicated that these improvements in HRQoL were

373 restricted to patients with high compliance (data not shown; n=21–35).

374

375376 Safety and adverse events data

A safety population was identified that included all patients who had completed at least
Visit 1 (n=2572).

380

381 A total of four adverse drug reactions (ADRs) were recorded in three patients (0.12%).

382 Two patients had one ADR and one patient had two. No serious ADRs were recorded

383 during DIAPAsOn.

384

385 Four deaths were recorded during the study, including one from cardiovascular

disease. None of those deaths were causally related to use of OM3EE.

- 388 There were 20 instances of hospitalization due to cardiovascular diseases, none of
- 389 which were attributed to use of OM3EE. Thirteen of these events affected participants

Page 13 of 44

- 390 who were being treated for hypertriglyceridemia, all of whom were also being
- 391 medicated with statins and/or fibrates.
- 392
- 393 OM3EE therapy was discontinued by 69 patients. Specified reasons for doing so
- 394 comprised inconvenience of use (n=11), lack of availability in pharmacies (n=6) and
- 395 lack of effect (n=2). Reasons for the remaining 50 discontinuations were recorded as
- 396 'other'.
- 397
- 398
- 399

Page 14 of 44

Discussion 400

401

402 Considered overall, the data from DIAPAsOn suggest that the introduction of OM3EE 403 had favorable effects on the blood lipid profile of our patients, consistent with 404 experience in previous controlled trials. As illustrated in Table 3 the percentage of 405 patients recorded as having TG <1.7 mmol/L guadrupled in response to OM3EE (from 13.1% at baseline to 54% at the conclusion of the study); conversely the percentage 406 of patients recorded as having TG >2.3 mmol/L fell to 10.4% from 66.9% at baseline. 407 These changes were accompanied by alterations in other lipoprotein fractions 408 409 compatible with an overall shift to a less atherogenic lipid profile, including reductions 410 in non-HDL-C which declined by an average 1.6+1.54 mmol/l. This pattern of 411 response to of OM3EE was substantially independent of the use or non-use of statins 412 by patients treated for hypertriglyceridemia (Table 4). 413 414 By implication, the levels of treatment adherence in both the digital and non-digital 415 contingents of DIAPAsOn were sufficient to achieve those effects, notwithstanding discrepancies in the level of adherence reported by the two groups of patients. 416

417

418 Among the analysis population in whom adherence was determined by in-clinic 419 guestioning adherence was consistently substantially higher in the post-MI subset 420 than the hypertriglyceridemia subset (Δ 10–20%). As survivors of a major cardiac 421 episode, those patients may be more motivated to continue with their medications than 422 patients with an invisible and asymptomatic condition. This indication of a motivation 423 element based on patients' clinical history is consistent with the findings of Gaisenok 424 et al. in the PROFILE registry [22], but not wholly sustained by the findings of the 425 ISLAND study [23]. Within the post-MI group adherence fell significantly at age >75 426 years (75.31% vs >87.5% for all younger age deciles; p=0.007, chi-square test).

427 Frequency of dosing may also be an influence on the discrepancy in adherence 428 between our two patient subgroups. The prescribed dose of OM3EE for secondary 429 prevention post-MI is 1 g/day, whereas that for hypertriglyceridemia is 2–4 g/day. The 430 up to fourfold difference in acquisition costs, plus the necessity of a twice-daily (vs 431 once-daily) dosing regimen, may have contributed to the lower adherence recorded in 432 the hypertriglyceridemia subgroup of DIAPAsOn, and perhaps to patients' views on

Page 15 of 44

the usability of OM3EE. However, the detailed patient interviews required to elucidatethis matter were not part of the study program.

435 'Very high' adherence was reported significantly more often by men than women, 436 especially in the hypertriglyceridemia subset (67.71% vs 60.38%; p=0.007, chi-square test). Among patients with hypertrialyceridemia, 'very high' adherence was also 437 significantly more likely in those who were recorded as not working (69.23% vs 438 59.66%; p<0.001, chi-square test), suggesting perhaps an effect of competing 439 440 priorities. Adherence was much higher among early school leavers than in any other category of education but, especially in the hypertriglyceridemia subset, this finding 441 442 was based on small numbers (n=3).

A further potentially strong influence on patient adherence and persistence is the personal beliefs of health professionals and general population attitudes. 'Therapeutic inertia' among physicians has been reported to contribute to poor management of cardiovascular risk factors in Russia and the USA [24,25]. The fact that 31% of the post-MI subgroup of DIAPAsOn were classified as current smokers may be indicative of attitudinal factors that operate to the general detriment of adherence.

A central purpose of DIAPAsOn was to examine how the use of digital technologies 449 450 might promote adherence to OM3EE therapy. This aspect of the study provides inconclusive and somewhat perplexing insights. The online facilities developed for 451 452 DIAPAsOn were used by 180 of the 2167 patients (8.3%) of the analysis population. 453 Response rates to surveys are highly variable and there are indications that, at least in 454 some instances, the rates of response to web-based exchanges are lower than are 455 achieved with paper-based methods [26]. Nevertheless, the costs of administering follow-up at scale are substantially lower using digital technology than traditional print-456 457 based methods and the flexibility and potential immediacy of contact between 458 physician and patient have a face-value attraction. Establishing why so many of our 459 patients declined to adopt this option would require in-depth interviewing of several 460 thousand patients and is beyond the resources of the study as originally conceived. 461 Similarly, we are not equipped to investigate whether or how physicians advocated for this aspect of the study during clinic visits or how patients responded to 462 463 encouragement.

Page 16 of 44

464 Adherence to therapy for patients self-reporting via the DIAPAsOn digital platform was defined as the total number of days when the patient took the full prescribed dose of 465 OM3EE during the specified period divided by the total number of days in that period. 466 Calculated in that way, adherence appeared to be low in these patients and declined 467 468 during the period of observation. However, we have no means of ascertaining whether 469 the data that patients recorded accurately reflected their true adherence to study 470 medication: actual adherence rates may therefore have been higher than the recorded findings suggest. Such a possibility would be compatible with the finding that in-study 471 472 trends in lipid and lipoprotein indices were favorable and numerically very similar in a 473 small group of digital adopters and the rest of the analysis population. We are unable 474 to demonstrate any such alignment of adherence rates, however, finding instead a notable discrepancy between adherence rates registered by users of the DIAPAsOn 475 476 app and those in whom adherence was assessed only at clinic visits despite broadly 477 similar lipid responses in both subgroups.

478 Comparison of the digital subset with the main analysis population also identified no 479 demographic differences between the two groups that might explain the adoption/non-480 adoption of the digital resources of DIAPAsOn. Wide-ranging technical obstacles 481 seem unlikely given the high level of smartphone penetration in Russia [27], general 482 access to the internet and the requirement for digital proficiency as an inclusion 483 condition. Average age (~58 years) is not, prima facie, a sufficient explanation for the 484 low level of digital uptake but may have exerted an influence that our study was not 485 calibrated to identify.

Seemingly at variance with the low level of adoption of the mobile technology devised for DIAPAsOn—and the apparently low levels of medication adherence reported by those patients that used the technology—is the observation that the dropout rate among the digital adopters was zero. The impression of a subset of patients who are tenacious in their adherence to technology but inattentive to their medications is a paradox that we are at present unable to rationalize.

Another finding of note in the digitally engaged patients was that HRQoL indices
showed a striking and sustained improvement among those who self-reported high
compliance. Patient numbers were small, the structure of an observational study
precludes determination of cause and effect and ascertaining reasons for this

Page 17 of 44

496 improvement lie outside the scope of our research. This is, nevertheless, an intriguing497 finding that would merit attention in future investigation.

498 The considered view of mobile- or internet-based health interventions to promote 499 adherence to therapy is that these innovations have potential but that both the quality and range of research need to be enhanced [28-30]. DIAPAsOn should be considered 500 501 in that context. One lesson that might be extracted from our findings is that patient engagement and participation in the development of an online or mobile telephony-502 503 based adherence aid might produce longer-term gains in terms of patients' willingness 504 to engage with the service once it is brought into daily use. DIAPAsOn might perhaps 505 have benefited from a small-scale scoping study or a pilot phase before the 506 technology was deployed in such a large patient population. Evaluation of our digital 507 platform by means of the Mobile Application Rating Scale [31] might also have helped 508 to refine the technology and enhance its acceptance by patients, and the failure to 509 apply that test in advance may be considered a missed opportunity. 510 One hazard of such an approach, however, is that by catering to the priorities of

511 patients well-disposed to mobile health technology the needs of 'digital exiles' are 512 overlooked. DIAPAsOn required some evidence of individual technical competence 513 from its patients but was otherwise non-restrictive in its eligibility criteria. To that extent 514 it has provided useful insights into the sort of real-world populations that might be 515 encountered (at least in Russia) and some of the challenges that these populations 516 pose for proponents of mobile or ehealth services.

517 As with observational studies in general, the absence of a control group precludes any 518 determination of cause and effect and the potential for biases in any trial of this type 519 must be acknowledged. A retrospective calculation of the Nichol score [32] for 520 DIAPAsOn confirmed that our study rated favorably in the subcategories 'Disease-521 Related Criteria' and 'Compliance Definition and Measurement Criteria' but scored 522 less strongly in the subcategory 'Study Design Criteria'. The duration of follow-up was 523 appropriate for a first assessment of a technical innovation but a substantially longer 524 period of observation would be needed to demonstrate robust and meaningful 525 improvements in long-term compliance and adherence, regardless of the methods or technologies used. 526

Page 18 of 44

528 Conclusions

529 Data from DIAPAsOn collected in our study confirm the clinical profile of OM3EE as 530 an effective and well-tolerated lipid-modifying therapy and as an appropriate element 531 of the medical regimen(s) for management of hypertriglyceridemia or the secondary prevention of MI. Substantial (~1 mmol/L) baseline-dependent reductions in TG were 532 recorded and other nominally advantageous alterations in the lipid profile were 533 apparent, including reduction in levels of non-HDL-C, regardless of the concomitant 534 use of statins and/or fibrates. Investigations into compliance with therapy produced 535 536 conflicting results depending on the method of reporting used. Uptake of digital 537 methods for self-reporting of adherence to therapy was low and indicates a need for further research into the factors that motivate or discourage patients to take advantage 538 539 of such services and of how best to use those technologies to promote treatment compliance. 540

Page 19 of 44

542	Funding and disclosure
543	
544	The study is supported by Abbott.
545	
546	GPA has not received any educational grants from any companies and has not
547	received any fees or non-financial support from healthcare companies related to this
548	study. GPA reports receiving honoraria for professional lectures at regional/national
549	medical educational events from healthcare companies, including Abbott, Bayer,
550	Boehringer Ingelheim, Servier.
551	
552	AGA has not received any educational grants from any companies and has not
553	received any fees or non-financial support from healthcare companies related to this
554	study. AGA reports receiving honoraria for professional lectures at regional/national
555	medical educational events from healthcare companies, including Abbott, Bayer,
556	Boehringer Ingelheim, Servier.
557	
558	FTA does not have any conflicts of interest.
559	
560	TVF does not have any conflicts of interest.
561	
562	
563	Acknowledgements
564	The investigators thank the Ethics Committee of Pirogov Russian National Research
565	Medical University for its advice and guidance on the development of the research
566	protocol.
567	Manuscript preparation was assisted by Hughes associates, Oxford, UK.

Page 20 of 44

- 569 Table 1. Trends in mean score on the National Questionnaire of Treatment
- 570 Compliance between baseline (Visit 1) and Visit 2 (3 months of study participation) or
- 571 Visit 3 (study completion, after 6 months).
- 572
- 573

Visit 1	Visit 2	Visit 3	Δ	p-value
12.5±3.11				
	12.99±2.88		V2–V1: 0.47±2.46	<0.001
		12.9±2.99	V3–V1: 0.44±2.52	<0.001

574

575

Page 21 of 44

- 577 Table 2. Baseline lipid profile of the analysis population, stratified by TG status,
- 578 identified progressively more atherogenic patterns of total and lipoprotein cholesterol
- 579 as TG levels increased.

580

TG (mmol/l)		TC (mmol/l)	TG (mmol/l)	LDL-C (mmol/l)	HDL-C (mmol/l)	n-HDL-C (mmol/l)
	Ν	282	282	282	282	280
<1.7	Mean	4.67	1.21	2.93	1.33	3.37
<1.7	SD	1.33	0.31	1.14	0.5	1.4
	Median	4.5	1.2	2.7	1.2	3.25
	Ν	431	431	430	431	431
1.7–2.3	Mean	5.31	2.04	3.39	1.31	4
1.7-2.3	SD	1.24	0.19	1.3	0.51	1.4
	Median	5.5	2.01	3.1	1.2	4.01
	Ν	1438	1438	1438	1438	1437
>2.3	Mean	5.79	3.63	3.65	1.25	4.55
>2.3	SD	1.37	1.08	1.22	0.44	1.42
	Median	5.9	3.4	3.5	1.1	4.6

Page 22 of 44

583 Table 3. Trends in overall TG levels during DIAPAsOn, stratified by baseline TG

584 category.

585

Visit	Deremeter		Baseline TG (mmol/l)						
VISIC	Parameter	<1.7	1.7–2.3	>2.3					
1	N		2151						
I	n/%	282/13.1	431/20	1438/66.9					
	N	2037							
2	n/%	787/38.6	670/32.9	580/28.5					
	p-value Visit 2–Visit 1	<0.001	<0.001	<0.001					
	N		1905						
3	n/%	1028/54	679/35.6	198/10.4					
	p-value Visit 3–Visit 1	<0.001	<0.001	<0.001					

Page 23 of 44

- 587 Table 4. Trends in lipid and lipoprotein fractions in patients enrolled in the analysis
- 588 population of DIAPAsOn for hypertriglyceridemia and receiving or not receiving
- 589 concomitant statins and/or fibrates.
- 590
- 591
- 592


	TC (mmol/l)	TG (mmol/l)	LDL-C (mmol/l)	HDL-C (mmol/l)	n-HDL-C (mmol/l)
		Sta	atins or fibrates: Y	ES	
V3–V1 mean±SD	-1.5±1.3	-1.7±1.2	-1.2±1.1	+0.2±0.5	-1.8±1.5
V3–V1 median	-1.44	-1.7	-1.0	+0.2	-1.9
P-value (V3 vs. V1)*	0.001	0.001	0.001	0.001	0.001
		Si	tatins or fibrates: N	10	
V3–V1 mean±SD	-1.4±1.3	-1.5±1.1	-0.84±0.9	0.3±0.6	-1.7±1.6
V3–V1 median	-1	-1.32	-0.7	+0.2	-1.3
P-value (V3 vs. V1)*	0.001	0.001	0.001	0.001	0.001

Page 24 of 44

- 594 Table 5. HRQoL data accrued from patients who contributed to the digital data-
- 595 collection element of DIAPAsOn. Differences (Visit 2- Visit 1) and (Visit 3- Visit 1) were
- 596 paired and therefore estimated only for those patients who were scored on both
- 597 relevant visits. Data for the 'General Health' domain were excluded due to a technical
- 598 error during data transfer.
- 599


Visit	Parameter	PF	RP	RE	E/F	EW	SF	Р
	Ν	82	82	82	82	82	82	82
1	Mean	22.36	39.02	53.25	43.82	52.9	58.54	74.45
	SD	16.18	44.11	41.2	21.62	16.1	26.34	31.16
	Ν	51	50	50	49	49	50	49
2	Mean	34.56	87.5	93.33	72.28	76.01	89.25	94.23
	SD	12.34	29.99	20.2	14.09	15.7	17.31	13.19
	Ν	35	35	35	35	35	35	35
2.4	Mean	7.63	32.86	25.71	20.81	22.66	26.43	8.43
2–1	SD	13.4	48.42	32.42	14.12	14.69	25.68	14.12
	p-value*	0.002	<0.001	<0.001	<0.001	<0.001	<0.001	0.001
	Ν	22	22	22	22	22	22	22
3	Mean	40.1	98.86	100	80.23	86.73	98.3	98.52
	SD	6.42	5.33	0	5.87	7.94	8	6.93
	N	22	22	22	22	22	22	22
2 1	Mean	6.69	29.55	18.18	18.18	25	16.48	-0.11
3–1	SD	10.08	43.39	30.39	13.59	14.65	25.41	0.53
	p-value*	0.005	0.004	0.011	<0.001	<0.001	0.006	0.329

Page 25 of 44




Page 26 of 44

- Figure 2. Distribution of adherence categories for the total study population and for the
- 606 two subpopulations (post-MI and hypertriglyceridemia) of the DIAPAsOn analysis
- 607 population, based on responses to the National Questionnaire of Treatment
- 608 Compliance.
- 609
- 610




Page 27 of 44


- Figure 3. In-study trends in blood lipids in the total study population and for the two
- subpopulations (post-MI and hypertriglyceridemia) of the DIAPAsOn analysis
- 614 population.
- 615
- 616
- 617
- 618



Blood lipid profile: Post-MI subgroup



Blood lipid profile: Hypertriglyceridaemia subgroup



- 619 620
- 621
- 622
- 623
- 624

Page 28 of 44

625 Supplementary Tables

626

627 Table S 1a. Assessment of the relationship between the rate of adherence and sex.

		Gender						
Visit	Parameter	Μ	ale	Female				
V ISIU	rarameter	Ν	Proportion (%)	N° Pt	Rate (%)			
	Total	1039	100	936	100			
	Low adherence	1	0.1	7	0.75			
	Moderate adherence	52	5	83	8.87			
Visit 1 –	High adherence	180	17.32	214	22.86			
Visit 3	Very high adherence	806	77.57	632	67.52			
	Mean questionnaire score	13	.23	12.53				
	p-value*		< 0.0	01				

628 Note: data are of the PP population, N = 2167; * χ -square.

629

630 Table S1b. Assessment of the relationship between the rate of adherence to therapy and

631 the sex of patients to whom OM3EE was prescribed as secondary preventive therapy

632 after myocardial infarction.

		Gender						
Visit	Parameter	Μ	ale	Female				
V ISIU	rarameter	Ν	Proportion (%)	N° Pt	Rate (%)			
	Total	528	100	252	100			
	Low adherence	0	0	0	0			
	Moderate adherence	10	1.89	7	2.78			
Visit 1 –	High adherence	58	10.98	26	10.32			
Visit 3	Very high adherence	460	87.12	219	86.9			
	Mean questionnaire	14	3.9	13.9				
	score	13.7 13.9						
	p-value*		0.93	8				

633 Note: data are of the PP population, N = 2167; * χ -square.

634

635

636

637

638

640 Table S1c. Assessment of the relationship between the rate of adherence to therapy and 641 sex among patients to whom OM3EE was prescribed for hypertriglyceridemia

		Gender						
Visit	Parameter	М	ale	Female				
V ISIL	rarameter	Ν	Proportion (%)	Ν	Proportion (%)			
	Total	511	100	684	100			
	Low adherence	1	0.2	7	1.02			
	Moderate adherence	42	8.22	76	11.11			
Visit 1 –	High adherence	122	23.87	188	27.49			
Visit 3	Very high adherence	346	67.71	413	60.38			
	Mean questionnaire score	12	.54	12.03				
	p-value*		0.0	07				

642 Note: data are of the PP population, N = 2167; $*\chi$ -square.

644 Table S2a. Assessment of the relationship between the rate of adherence and age.

645

					Age	group			
Visit	Parameter		18-44		45-60	61-75		>75	
V 1511	rarameter	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)
	Total	231	100	768	100	804	100	172	100
	Low adherence	1	0.43	3	0.39	4	0.5	0	0
	Moderate adherence	21	9.09	52	6.77	48	5.97	14	8.14
Visit 1 – Visit 3	High adherence	55	23.81	167	21.74	137	17.04	35	20.35
VISIC 5	Very high adherence	154	66.67	546	71.09	615	76.49	123	71.51
	Mean questionnaire score		12.45		12.78		13.15		12.87
	p-value*			•	0.	007		-	

⁶⁴⁶ Note: data are of the PP population, N = 2167; * χ -square.

647

648

⁶⁴³

Page 30 of 44

Table S2b. Assessment of the relationship between the rate of adherence to therapy and 650

the age of patients to whom OM3EE was prescribed as secondary preventive therapy 651

after myocardial infarction. 652

653

					А	ge gro	oup		
Visit	Parameter		18-44		45-60		61-75	>75	
v isit	rarameter	N	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	N	Proportion (%)
	Total	48	100	273	100	378	100	81	100
	Low adherence	0	0	0	0	0	0	0	0
	Moderate adherence	1	2.08	3	1.1	8	2.12	5	6.17
Visit 1 – Visit 3	High adherence	5	10.42	25	9.16	39	10.32	15	18.52
VISIC 5	Very high adherence	42	87.5	245	89.74	331	87.57	61	75.31
	Mean questionnaire score		13.92		14.06		13.95		13.14
	p-value*			•		0.007	7		

654 Note: data are of the PP population, N = 2167; * χ -square.

655

- 656
- 657
- Table S2c. Assessment of the relationship between the rate of adherence to therapy and 658
- 659 age among patients to whom OM3EE was prescribed for hypertriglyceridemia.
- 660

					Ag	ge grou	ъ			
Visit	Parameter		18-44		45-60		61-75	>75		
VISIC		Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	
	Total	183	100	495	100	426	100	91	100	
	Low adherence	1	0.55	3	0.61	4	0.94	0	0	
	Moderate adherence	20	10.93	49	9.9	40	9.39	9	9.89	
Visit 1 – Visit 3	High adherence	50	27.32	142	28.69	98	23	20	21.98	
visit 5	Very high adherence	112	61.2	301	60.81	284	66.67	62	68.13	
	Mean questionnaire score		12.07		12.07		12.44		12.64	
	p-value*					0.19				

661 Note: data are of the PP population, N = 2167; * χ -square.

Page 31 of 44

662 Table S3a. Assessment of the relationship between the rate of adherence and work status.

			Work	status					
Visit	Parameter	W	orks	Does not work					
VISIC	1 al ameter	Ν	Proportion (%)	Ν	Proportion (%)				
	Total	1096	100	879	100				
	Low adherence	5	0.46	3	0.34				
	Moderate adherence	85	7.76	50	5.69				
Visit 1 – Visit 3	High adherence	251	22.9	143	16.27				
v ISIL I = v ISIL J	Very high adherence	755	68.89	683	77.7				
	Mean questionnaire	1	2.66		13.2				
	score	1	2.00		15.2				
	p-value*		<0.001						

663 Note: data are of the PP population, N = 2167; * χ -square.

664

665

Table S3b. Assessment of the relationship between the rate of adherence to therapy and work status of patients to whom OM3EE was prescribed as secondary preventive therapy after myocardial infarction.

		Work status							
Visit	Parameter		Works	Does not work					
VISIU	Farameter	Ν	Proportion (%)	Ν	Proportion (%)				
	Total	382	382 100 398		100				
	Low adherence	0	0	0	0				
	Moderate adherence	6	1.57	11	2.76				
Visit 1 – Visit 3	High adherence	47	12.3	37	9.3				
v ISIU I - v ISIU S	Very high adherence	329	86.13	350	87.94				
	Mean questionnaire		13.9		13.9				
	score		13.7	13.9					
	p-value*		0.99						

669 Note: data are of the PP population, N = 2167; * χ -square.

670

672 Table S3c. Assessment of the relationship between the rate of adherence to therapy and work status among patients to whom OM3EE was prescribed for hypertriglyceridemia. 673

			Work status							
Visit	Parameter	l l	Works	Does not work						
VISIU	Farameter	Ν	Proportion (%)	Ν	Proportion (%)					
	Total	714	100	481	100					
	Low adherence	5	0.7	3	0.62					
	Moderate adherence	79	11.06	39	8.11					
Visit 1 – Visit 3	High adherence	204	28.57	106	22.04					
v ISIL I = v ISIL J	Very high adherence	426	59.66	333	69.23					
	Mean questionnaire score		11.99	12.62						
	p-value*		0.001							

674 Note: data are of the PP population, N = 2167; $*\chi$ -square.

675

676

677

678 Table S4a. Assessment of the relationship between the rate of adherence and education.

679

]	Education				
Visit	Parameter	Secondary education drop- out			Secondary general		econdary ocational		Higher	Supplementary vocational	
		N	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	N	Proportion (%)	Ν	Proportion (%)
	Total	15	100	224	100	634	100	1064	100	38	100
	Low adherence	0	0 0		1.34	3	0.47	2	0.19	0	0.19
	Moderate adherence	0	0	24	10.71	56	8.83	52	4.89	3	4.89
Visit 1 – Visit 3	High adherence	1	6.67	67	29.91	121	19.09	192	18.05	13	18.05
VISIC 5	Very high adherence	14	93.33	130	58.04	454	71.61	818	76.88	22	76.88
	Mean questionnaire score		14.27	11.91			12.67		13.25		12.21
	p-value*						< 0.001				

680 Note: data are of the PP population, N = 2167; * χ -square.

681

Page 33 of 44

683 Table S4b. Assessment of the relationship between the rate of adherence to therapy and education of 684 patients to whom OM3EE was prescribed as secondary preventive therapy after myocardial 685 infarction.

]	Education				
Visit	Parameter	Secondary education drop- out		S	Secondary general		econdary ocational		Higher	Supplementary vocational	
		N	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	N	Proportion (%)
	Total	12	100	78	100	258	100	419	100	13	100
	Low adherence	0	0 0		0	0	0	0	0	0	0
	Moderate adherence	0	0	3	3.85	8	3.1	6	1.43	0	1.43
Visit 1 – Visit 3	High adherence	1	8.33	12	15.38	24	9.3	46	10.98	1	10.98
VISIT 5	Very high adherence	11	91.67	63	80.77	226	87.6	367	87.59	12	87.59
	Mean questionnaire score	14.17			13.46		13.84		14.01	14.15	
	p-value*						0.3				

687 Note: data are of the PP population, N = 2167; * χ -square.

688

689

690 Table S4c. Assessment of the relationship between the rate of adherence to therapy and 691 education among patients to whom OM3EE was prescribed for hypertriglyceridemia.

						I	Education				
Visit	Parameter	Secondary education drop-out			Secondary general		econdary ocational		Higher	Supplementary vocational	
		N	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)
	Total	3	100	146	100	376	100	645	100	25	100
	Low adherence	0	0 0		2.05	3	0.8	2	0.31	0	0.31
	Moderate adherence	0	0	21	14.38	48	12.77	46	7.13	3	7.13
Visit 1 – Visit 3	High adherence	0	0	55	37.67	97	25.8	146	22.64	12	22.64
VISIC 5	Very high adherence	3	100	67	45.89	228	60.64	451	69.92	10	69.92
	Mean questionnaire score		14.67		11.08		11.88		12.76	11.2	
	p-value*						< 0.001				

692 Note: data are of the PP population, N = 2167; * χ -square.

Page 34 of 44

694 Table S5a. Assessment of the relationship between the rate of adherence and marital status.

					Mari	tal statu	15		
Visit	Parameter	Single		Μ	arried		Divorced	Widowed	
VISIC	r ar anneter	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)
	Total	82	100	1593	100	114	100	186	100
	Low adherence	0	0	7	0.44	1	0.88	0	0
	Moderate adherence	13	15.85	102	6.4	8	7.02	12	6.45
Visit 1 – Visit 3	High adherence	13	15.85	320	20.09	24	21.05	37	19.89
v ISIL S	Very high adherence	56	68.29	1164	73.07	81	71.05	137	73.66
	Mean questionnaire score		12.5		12.91	12.76		13.08	
	p-value*				(0.49			

696

697

698

699Table S5b. Assessment of the relationship between the rate of adherence to therapy and marital700status of patients to whom OM3EE was prescribed as secondary preventive therapy after

701 myocardial infarction.

					Marita	l stat	tus		
Visit	Parameter	Single]	Married		Divorced	Widowed	
V ISIL		N	Proportion (%)	Ν	Proportion (%)	N	Proportion (%)	Ν	Proportion (%)
	Total	31	100	574	100	57	100	118	100
	Low adherence	0	0	0	0	0	0	0	0
Visit	Moderate adherence	4	12.9	7	1.22	3	5.26	3	2.54
1 - Visit	High adherence	6	19.35	55	9.58	5	8.77	18	15.25
3	Very high adherence	21	67.74	512	89.2	49	85.96	97	82.2
	Mean questionnaire score		12.58		14.01		13.79		13.8
	p-value*				0.0)04			

702 Note: data are of the PP population, N = 2167; * χ -square.

703

705 Table S5c. Assessment of the relationship between the rate of adherence to therapy and marital status among patients to whom OM3EE was prescribed for hypertriglyceridemia. 706

					Marital	statu	IS		
Visit	Parameter	Single		Ν	Aarried		Divorced	Widowed	
v ISIL		N	Proportion (%)	N	Proportion (%)	Ν	Proportion (%)	Ν	Proportion (%)
	Total	51	100	1019	100	57	100	68	100
	Low adherence	0	0	7	0.69	1	1.75	0	0
Visit	Moderate adherence	9	17.65	95	9.32	5	8.77	9	13.24
Visit 1 – Visit	High adherence	7	13.73	265	26.01	19	33.33	19	27.94
3	Very high adherence	35	68.63	652	63.98	32	56.14	40	58.82
	Mean questionnaire score		12.45		12.29		11.74	11.84	
	p-value*			•	0.4	2		•	

707 Note: data are of the PP population, N = 2167; * χ -square.

Page 36 of 44

709 Appendix 1. Listing of DIAPASoN center investigators.

Region		Investigator
5		ç
Astrakhan Oblast	1.	Borodulya Mihail Vasil'evich
Bryansk Oblast	2.	Petuhova Irina Leonidovna
Vladimir Oblast	3.	Timofeeva Irina Vladimirovna
	4.	Vorob'eva Svetlana Gennad'evna
	5.	Gulova Ol'ga Aleksandrovna
Volgograd Oblast	6.	Dugencova Larisa Anatol'evna
	7.	Sytilina Natal'ya Nikolaevna
Voronezh Oblast	8.	Trubicyna Irina Valentinovna
Kemerovo Oblast	9.	Krestova Ol'ga Sergeevna
	10.	Alekseeva Elena Valer'evna
	11.	Allaabed Hassan Adnanovich
	12.	Bahmet'eva Irina Aleksandrovna
	13.	Boldin Vasilij Borisovich
	14.	Vikulova Larisa Vladimirovna
	15.	Golovko Artyom Yur'evich
	16.	Emuzova Liana Anatol'evna
Krasnodar Krai	17.	Zaharov Aleksandr Yur'evich
	18.	Ivochkina Marina Ivanovna
	19.	Imamutdinova Marina Vladimirovna
	20.	Kovalenko Fyodor Andreevich
	21.	Minasyan Ani Kamoevna
	22.	Mkrtycheva Angelina Gennad'evna
	23.	Nikitina Elena Valer'evna
	24.	Novikova Svetlana Valer'evna

Region		Investigator
	25.	Pavlovec Vadim Petrovich
	26.	Perkova Elena Mihajlovna
	27.	Prozorovskaya Yuliya Igorevna
	28.	Ramenskaya Tat'yana Evgen'evna
	29.	Raff Stanislav Anatol'evich
	30.	Smolina Elena Garievna
	31.	Subbotina Anastasiya Vladimirovna
	32.	Tatarinceva Zoya Gennad'evna
	33.	Usmanova Natal'ya Aleksandrovna
	34.	Hazhbieva Milana Musaevna
	35.	Shadzhe Evgeniya Azamatovna
Krasnoyarsk Krai	36.	Hamyt- Kyzy Ajperi Hamytovna
	37.	Adamyan Margarita Mamikonovna
	38.	Belov Leonid L'vovich
Moscow	39.	Brodichko Alena Ivanovna
	40.	Bugaev Timofej Dmitrievich
	41.	Vahrulina Natal'ya Konstantinovna
	42.	Grigor'eva Ekaterina Anatol'evna
	43.	Dvorina Ol'ga Gennad'evna
	44.	Dmitrieva Irina Mihajlovna
	45.	Karaeva Aida Anzorovna
	46.	Novosel'ceva Ekaterina Pavlovna
	47.	Oganesyan Lala Konstantinovna
	48.	Polyakova Natal'ya Olegovna
	49.	Ryzhova Tat'yana Vladimirovna
	50.	Smirnova Ol'ga L'vovna

Page 38 of 44

	· · · · · · · · · · · · · · · · · · ·
Region	Investigator
	51. Tavleeva Svetlana Nikolaevna
	52. Hrulenko Svetlana Borisovna
	53. Chernushenko Tat'yana Ivanovna
	54. Gukov Konstantin Aleksandrovich
	55. Gukova Tat'yana Sergeevna
Moscow Oblast	56. Malyarenko Elena Nikolaevna
	57. Sorokin Sergej Anatol'evich
	58. Abramova Nataliya Arkad'evna
	59. Aksenova Nataliya Aleksandrovna
	60. Barsukova Nataliya Aleksandrovna
	61. Budarina Yuliya Gennad'evna
Nizhny Novgorod Oblast	62. Grushin Dmitrij Valer'evich
	63. Kolesnichenko Irina Vyacheslavovna
	64. Lokonova Larisa Mihajlovna
	65. Fedorova Svetlana Nikolaevna
Novosibirsk Oblast	66. Shurkevich Anastasiya Alekseevna
	67. Minzhasarova Saniya Hasangalievna
Omsk Oblast	68. Naumov Dmitrij Valer'evich
Perm Krai	69. Zhuravleva Natal'ya Alekseevna
The Republic of Adygea	70. Shekhmirzova Dzhanetta Ruslanovna
	71. Gilyaeva El'vira Fanisovna
The Republic of Bashkortostan	72. Dmitriev Aleksej Valer'evich
	73. Murasova Rimma Ismagilovna
	74. Tarzimanova Yuliya Shamilevna
	75. Timerbulatov Timur Rasfarovich
Tatarstan	76. Ivanova Natal'ya Mihajlovna

Page 39 of 44

Region		Investigator
	77.	Budanova Ol'ga Veniaminovna
	78.	Lobe Aleksandra Ovanesovna
Rostov Oblast	79.	Mazruho Marina Karpovna
	80.	Morgun Nina Karpovna
	81.	Stupina Anna Alekseevna
Ryazan Oblast	82.	Grusheckaya Irina Stanislavovna
	83.	Samarceva Yana Nikolaevna
	84.	Aristova Tat'yana Vladimirovna
	85.	Reznik Irina Mihajlovna
	86.	Rybina Evgeniya Dmitrievna
Samara Oblast	87.	Sapunkova Svetlana Mihajlovna
	88.	Filippovskaya Natal'ya Igorevna
	89.	Chernova Viktoriya Nikolaevna
	90.	Bulycheva-Samohina Lyubov' Vasil'evna
Saint Petersburg	91.	Omel'chenko Marina Yur'evna
	92.	Saf'yanova Natal'ya Viktorovna
Saratov Oblast	93.	Mihajlova Elena Aleksandrovna
Smolensk Oblast	94.	Novik Lyudmila Mihajlovna
	95.	Vedeneva Elena Viktorovna
Stavropol Krai	96.	Eremenko Aleksej Mihajlovich
	97.	Kubanova Asiyat Borisovna
	98.	Minasova Elena Nikolaevna
Tomsk Oblast	99.	Zubova Ol'ga Valer'evna
Tula Oblast	100.	Barabanova Tat'yana Yur'evna
	101.	Dabizha Viktoriya Gennad'evna
	102.	Kolomejceva Tat'yana Mihajlovna

Region		Investigator
	103.	Prihod'ko Tat'yana Nikolaevna
Tumen Oblast	104.	Ahshiyatova Nastya Ibragimovna
Khabarovsk Krai	105.	Koroleva Ramilya Lotfullovna
Chelyabinsk Oblast	106.	Malyutina Anastasiya Gennad'evna
	107.	Fanina El'vira Rinatovna

Page 41 of 44

715 **References**

- 716
- Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617-670. doi:10.2147/VHRM.S37119
- 722
- 723 724

725

726

727

731

734

739

743 744

745

- Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015;65:2267e75.
- Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD Risk
 Reduction: Recent Insights and Future Directions. *Curr Atheroscler Rep.* 2020;22(7):25. Published 2020 Jun 3. doi:10.1007/s11883-020-00846-8
- 4. Morrison A, Hokanson JE. The independent relationship between triglycerides
 and coronary heart disease. Vasc Health Risk Manag 2009:5 89–95.
- 5. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P,
 Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard
 CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk
 of vascular disease. JAMA 2009;302:1993–2000.
- 6. Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic Dyslipidaemia and
 Cardiovascular Disease. *Eur Cardiol.* 2020;15:1-9. Published 2020 Feb 26.
 doi:10.15420/ecr.2019.06
 - Vallejo-Vaz AJ, Corral P, Schreier L, Ray KK. Triglycerides and residual risk. *Curr Opin Endocrinol Diabetes Obes*. 2020;27(2):95-103. doi:10.1097/MED.00000000000530
- Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular
 disease: a scientific statement from the American Heart Association.
 Circulation. 2011;123(20):2292-2333. doi:10.1161/CIR.0b013e3182160726
- 751 752
- 9. Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual
 Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease
 Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition
 Examination Survey 2007-2014. *Diabetes Care*. 2019;42(12):2307-2314.
 doi:10.2337/dc19-0501
- 758

Page 42 of 44

759	10.Brown WV, Jacobson TA, Braun LT. Achieving adherence to lipid-lowering
760	regimens. J Clin Lipidol. 2013;7(1):4-13. doi:10.1016/j.jacl.2012.11.004
761	
762	11. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost
763	opportunity. Pharmacotherapy. 2001;21(5):576-582.
764	doi:10.1592/phco.21.6.576.34541
765	
766	12. lakunchykova O, Averina M, Wilsgaard T, et al. Why does Russia have such
767	high cardiovascular mortality rates? Comparisons of blood-based biomarkers
768	with Norway implicate non-ischaemic cardiac damage. J Epidemiol Community
769	Health Published Online First: 15 May 2020. doi: 10.1136/jech-2020-213885.
770	
771	13. Boytsov S, Logunova N, Khomitskaya Y; CEPHEUS II investigators.
772	Suboptimal control of lipid levels: results from the non-interventional Centralized
773	Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II
774	(CEPHEUS II). <i>Cardiovasc Diabetol</i> . 2017;16(1):158. Published 2017 Dec 16.
775 776	doi:10.1186/s12933-017-0641
770	14. Cybulsky M, Cook S, Kontsevaya AV, Vasiljev M, Leon DA. Pharmacological treatment
778	of hypertension and hyperlipidemia in Izhevsk, Russia. BMC Cardiovasc Disord.
779	2016;16:122. Published 2016 Jun 3. doi:10.1186/s12872-016-0300-9
780	
781	15. Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin
782	persistence is poor among high-risk patients with dyslipidemia: a real-world
783	administrative claims analysis. Lipids Health Dis. 2019;18(1):175. Published
784	2019 Sep 16. doi:10.1186/s12944-019-1099-z
785	
786	16. Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T. Post-
787	myocardial Infarction (MI) Care: Medication Adherence for Secondary
788	Prevention After MI in a Large Real-world Population. Clin Ther.
789	2019;41(1):107-117. doi:10.1016/j.clinthera.2018.11.012
790	17. Gutstein AS, Copple T. Cardiovascular disease and omega-3s: Prescription
790 791	products and fish oil dietary supplements are not the same. J Am Assoc Nurse
792	Pract. 2017;29(12):791-801. doi:10.1002/2327-6924.12535
793	
794	18. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the
795	primary and secondary prevention of cardiovascular disease. Cochrane
796	Database Syst Rev. 2020;3(2):CD003177. Published 2020 Feb 29.
797	doi:10.1002/14651858.CD003177.pub5
798	19. Redfern J. Smart health and innovation: facilitating health-related behaviour
799	change. Proc Nutr Soc. 2017;76(3):328-332. doi:10.1017/S0029665117001094
800	
801	20. Arutyunov GP, Arutyunov AG, Ageev FT, Fofanova TV. Use of digital
802	technology tools to examine patient adherence to a prescription omega-3
803	polyunsaturated acids therapy intended to mitigate cardiovascular risk: protocol
804	and preliminary demographic data from the DIAPAsOn prospective

Page 43 of 44

805 806 807	observational study. J Med Internet Res Prot. JMIR Res Protoc. 2021 Aug 30;10(8):e29061. doi: 10.2196/29061. PMID: 34459746; PMCID: PMC8438613
807 808 809 810 811 812	21. Fofanova T.V., Ageev F.T., Smirnova M.D., Svirida O.N., Kuzmina A.E., Thostov A.Sh., Nelyubina A.S. National questionnaire of treatment compliance: testing and application in outpatient practice // Systemic hypertension #2 2014, p. 13-16
812 813 814 815 816 817	22. Gaisenok O, Martsevich S, Tripkosh S, Lukina Y. Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. <i>Rev Port Cardiol.</i> 2015;34(2):111-116. doi:10.1016/j.repc.2014.08.021
818 819 820 821	 Ivers NM, Schwalm JD, Bouck Z, et al. Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial. <i>BMJ</i>. 2020;369:m1731. Published 2020 Jun 10. doi:10.1136/bmj.m1731
822 823 824 825 826 827	24. Drozdova LY, Martsevich SY, Voronina VP. Evaluation of cardiovascular risk factors prevalence and efficacy of their correction in physicians. Estimation of physicians' expertise in up-to-date clinical guidelines. Results of the "Physician's health and education" study. Ration Pharmacother Cardiol. 2011;7(2):137–144 [Russian]
828 829 830 831	25. Bradley CK, Wang TY, Li S, et al. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019;8(7):e011765. doi:10.1161/JAHA.118.011765
832 833 834 835 836	26. Sebo P, Maisonneuve H, Cerutti B, Fournier JP, Senn N, Haller DM. Rates, Delays, and Completeness of General Practitioners' Responses to a Postal Versus Web-Based Survey: A Randomized Trial. <i>J Med Internet Res</i> . 2017;19(3):e83. Published 2017 Mar 22. doi:10.2196/jmir.6308
837 838	27. https://www.statista.com/statistics/467166/forecast-of-smartphone-users-in-russia/
839 840 841 842 843	28. Gandapur Y, Kianoush S, Kelli HM, et al. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. <i>Eur Heart J Qual Care Clin Outcomes</i> . 2016;2(4):237-244. doi:10.1093/ehjqcco/qcw018
844 845 846 847 848	29. Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. <i>J Med Internet Res.</i> 2015;17(2):e52. Published 2015 Feb 24. doi:10.2196/jmir.3951

849 850 851 852 853	30. Adler AJ, Martin N, Mariani J, et al. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. <i>Cochrane Database Syst Rev.</i> 2017;4(4):CD011851. Published 2017 Apr 29. doi:10.1002/14651858.CD011851.pub2
854	
855	31. Stoyanov SR, Hides L, Kavanagh DJ, Zelenko O, Tjondronegoro D, Mani M.
856	Mobile app rating scale: a new tool for assessing the quality of health mobile
857	apps. JMIR Mhealth Uhealth. 2015;3(1):e27. doi: 10.2196/mhealth.3422.
858	
859	32. Nichol MB, Venturini F, Sung JCY. A critical evaluation of the methodology of
860	the literature on medication compliance. Ann Pharmacother 1999;33:531-40.
861	
862	
863	
864	
865	